z-logo
open-access-imgOpen Access
Anticancer activity of Eugenia jambolana seeds against Hep2 cell lines
Author(s) -
Denis Mabeya Ogato,
Eliakim Mbaka Mauti,
Godfrey Omare Mauti,
Barasa Ambrose,
David Keno Kowanga
Publication year - 2016
Publication title -
the journal of phytopharmacology
Language(s) - English
Resource type - Journals
ISSN - 2320-480X
DOI - 10.31254/phyto.2015.4604
Subject(s) - diluent , traditional medicine , glycoside , berry , mtt assay , phenols , chemistry , viability assay , botany , biology , cell , medicine , biochemistry , nuclear chemistry
Cancer is a life-threatening disease and leads to high rates of mortality worldwide, after cardiovascular disease, is the second leading cause of death. Investigations for finding new plant based anticancer compounds are imperative and interesting. There are many studies on anticancer herb/plant extracts in cell line models. Eugenia jambolana has been reported to contain phytochemicals like coumarin, flavanoids, glycosides, phenols, tannins and steroids. The various part of Eugenia jambolana have therapeutic applications. Plant active components were extracted using the decoction extraction method and the filtrate was obtained by means of filtering through a Whattman no.1 filter paper. The filtrate was evaporated in a weighed flask in a hot air oven set at 50°C. Extracts were reconstituted by re-dissolving in respective solvents. Different concentration i.e. 8, 15.6, 31.25, 62.5, 125, 250, 500 and 1000 µg. of the plant extracts were tested for the anticancer activity. The anticancer assay was performed on Human laryngeal epithiloma cells (Hep 2) obtained from King Institute of Preventive Medicine, Chennai, India. The cell viability was measured using MTT assay. Controls were maintained throughout the experiment (Untreated wells as cell control and diluent treated wells as diluent control). The assay was performed in triplicates for each of the extracts.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here